Why Vitamin A is Given in Measles
Vitamin A supplementation is mandatory for all children with measles because it reduces mortality by 64% and pneumonia-specific mortality by 67%, particularly in children under 2 years of age, even in populations without clinically apparent vitamin A deficiency. 1
Mechanism and Rationale
Measles infection causes acute vitamin A depletion regardless of baseline nutritional status, with 92% of hospitalized children demonstrating biochemical hyporetinemia (serum retinol <0.7 μmol/L) even in populations where clinical vitamin A deficiency is rare. 2 This acute depletion directly increases disease severity and mortality risk. 3
Evidence-Based Dosing Protocol
Standard Two-Dose Regimen (Mandatory)
- Children ≥12 months (including adults): 200,000 IU orally on day 1 1, 3
- Children <12 months: 100,000 IU orally on day 1 1, 3
Enhanced Protocol for Complicated Measles
- Administer an identical second dose on day 2 when any of the following complications are present: 1
- Pneumonia
- Otitis media
- Croup
- Diarrhea with moderate or severe dehydration
- Neurological problems
This two-dose regimen demonstrates superior outcomes compared to single-dose protocols, with an 82% mortality reduction specifically in children under 2 years (RR 0.18). 1
Extended Protocol for Vitamin A Deficiency Eye Signs
- When xerosis, Bitot's spots, keratomalacia, or corneal ulceration are observed, give a third dose 1-4 weeks after the initial treatment (same age-based dosing). 1
Clinical Outcomes Improved by Vitamin A
The evidence demonstrates multiple benefits beyond mortality reduction:
- Faster recovery from pneumonia: 6.3 days versus 12.4 days in controls (P <0.001) 2
- Reduced duration of diarrhea: 5.6 days versus 8.5 days, with a mean reduction of 1.92 days (P <0.001) 2, 4
- 47% reduction in croup incidence (RR 0.53,95% CI 0.29-0.89) 4
- 74% reduction in otitis media (RR 0.26,95% CI 0.05-0.92) 4
- Shorter hospital stays: 10.6 days versus 14.8 days (P = 0.01) 2
Critical Implementation Pitfalls
Major gap in clinical practice: Only 33% of children hospitalized for measles in US hospitals receive vitamin A supplementation despite universal recommendations, with children having complex chronic conditions even less likely to be treated. 5 This represents a dangerous deviation from evidence-based care.
Formulation matters: Water-based vitamin A preparations show an 81% mortality reduction (RR 0.19) compared to 48% with oil-based preparations (RR 0.52), though both are effective. 4
Single-dose regimens are insufficient: Studies using only one 200,000 IU dose showed no significant mortality reduction (RR 0.77,95% CI 0.34-1.78), making the two-dose protocol essential for complicated cases. 4, 6
High-Income Country Considerations
One recent Italian study found no benefit of vitamin A in hospitalized children in a high-income setting. 7 However, this contradicts the overwhelming body of evidence and international guidelines. The WHO, CDC, and AAP maintain universal vitamin A supplementation recommendations for all children with measles regardless of country income level, as measles-induced vitamin A depletion occurs independently of baseline nutritional status. 1, 3 The Italian study's negative findings may reflect differences in baseline vitamin A stores, disease severity, or study design limitations, but do not override the strong evidence base supporting supplementation.
Safety Profile
The only documented adverse effect is transient vomiting within 48 hours of administration (RR 1.97,95% CI 1.44-2.69), which is clinically insignificant compared to the mortality benefit. 8